Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Arun Chandrasekharan"'
Autor:
Vijay Patil, Vanita Noronha, Sameer Shrirangwar, Nandini Menon, George Abraham, Arun Chandrasekharan, Kumar Prabhash
Publikováno v:
Cancer Medicine, Vol 10, Iss 19, Pp 6725-6735 (2021)
Abstract Background There are limited data from low‐ to middle‐income countries (LMIC) on the incidence, risk factors, treatment outcomes, and antibiotic susceptibility spectrum of aspiration pneumonia (AsP). Methods We conducted a post hoc analy
Externí odkaz:
https://doaj.org/article/8865fbf185594cc1b02bbbbd7bdbbe4c
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 5, Iss 4, Pp 785-787 (2022)
Externí odkaz:
https://doaj.org/article/b313e28360fc4f0db94bd258b850f85d
Autor:
Vijay M. Patil, Nandini Menon, Abhishek Chatterjee, Raees Tonse, Amit Choudhari, Abhishek Mahajan, Ameya D. Puranik, Sridhar Epari, Monica Jadhav, Shruti Pathak, Zoya Peelay, Rutuja Walavalkar, Hemanth K. Muthuluri, Madala Ravi Krishna, Arun Chandrasekharan, Nikhil Pande, Tejpal Gupta, Shripad Banavali, Rakesh Jalali
Publikováno v:
EClinicalMedicine, Vol 49, Iss , Pp 101449- (2022)
Summary: Background: Recurrent glioblastoma (GBM) has dismal outcomes and limited treatment options. Mebendazole (MBZ) has activity in glioma both in-vivo and in-vitro, and is well tolerated in combination with lomustine (CCNU) and temozolomide (TMZ)
Externí odkaz:
https://doaj.org/article/e4971882039442a38189da5c4a093f24
Autor:
Arun Chandrasekharan
Publikováno v:
South Asian Journal of Cancer, Vol 11, Iss 03, Pp 181-182 (2022)
Externí odkaz:
https://doaj.org/article/89944805731b47c196f5866e7cf6e6e9
Autor:
Jyoti Bajpai, George Abraham, Avanish P. Saklani, Anshul Agarwal, Sashanka Das, Ambarish Chatterjee, Akhil Kapoor, Prathyusha Eaga, Pradip Kumar Mondal, Arun Chandrasekharan, Prabhat Ghanshyam Bhargava, Sujay Srinivas, Siddharth Turkar, Bharat Rekhi, Nehal Khanna, Amit Kumar Janu, Munita Bal, Vikas Sureshchand Ostwal, Anant Ramaswamy, Jitender Rohila, Ashwin L. Desouza, Amrita Guha, Rajiv Kumar, Nandini Sharrel Menon, Sushmita Rath, Vijay Maruti Patil, Vanita Maria Noronha, Amit Prakashchandra Joshi, Siddhartha Laskar, Venkatesh Rangarajan, Kumar Prabhash, Sudeep Gupta, Shripad Banavali
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTreatment of malignant melanoma has undergone a paradigm shift with the advent of immune checkpoint inhibitors (ICI) and targeted therapies. However, access to ICI is limited in low-middle income countries (LMICs).Patients and MethodsHistol
Externí odkaz:
https://doaj.org/article/09b0201bc3804bcf8f43a6dd061e0ff6
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 1, Pp 110-112 (2020)
Externí odkaz:
https://doaj.org/article/d494766f6468459c96de1cdf339fb479
Autor:
M S Anuja, Arun Chandrasekharan
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 5, Iss 4, Pp 784-785 (2022)
Externí odkaz:
https://doaj.org/article/c88189b52be34591973c3d936fb85ab6
Autor:
Vijay M Patil, Amit Joshi, Vanita Noronha, Vikas Talreja, Vijai Simha, Sachin Dhumal, Bhavesh Bandekar, Arun Chandrasekharan, Kumar Prabhash
Publikováno v:
South Asian Journal of Cancer, Vol 8, Iss 3, Pp 173-177 (2019)
Introduction: Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma nasopharynx and studied their outcomes. Methods: Patients who underwent first-line palliative systemi
Externí odkaz:
https://doaj.org/article/66fca4b1929c4799ac0af3172c82e053
Autor:
Sachin Dhumal, Arun Chandrasekharan, Vijay Patil, Vanita Noronha, Amit Joshi, Ameya Puranik, Venkatesh Rangarajan, Kumar Prabhash
Publikováno v:
South Asian Journal of Cancer, Vol 8, Iss 3, Pp 185-188 (2019)
Externí odkaz:
https://doaj.org/article/9a44741ef4ff44ea93c98b3712a9d8d7
Autor:
Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Nandini Menon, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 2, Iss 1, Pp 21-27 (2019)
Background:> In an open-label, Phase III randomized study, gefitinib was found to be superior to pemetrexed-platinum in terms of progression-free survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. In
Externí odkaz:
https://doaj.org/article/8fcf2089e596474fad6dd1c14c9fcfe1